Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICT01 + IL-2 +/- Pembrolizumab in Advanced Solid Tumors
NCT05307874Phase 2Terminated
- Sponsor
- ImCheck Therapeutics
- Start
- May 2022
- Primary completion
- Oct 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of Ichnocim in solid tumor, sponsored by ImCheck Therapeutics. Started May 2022; status: terminated.
02
Drugs
Ichnocim
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05307874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05307874.